Comparing the current results to its competitors, Akoya Biosciences Inc reported Revenue decrease in the 1 quarter 2025 year on year by -8.68 %, faster than the overall decrease of Akoya Biosciences Inc 's competitors by -0.69 %, recorded in the same quarter.
Akoya Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 0.04 %
Akoya Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the spatial biology market, serving a customer base that includes biopharmaceutical companies, academic research centers, and governmental institutions globally. It faces competition from several companies with products that compete to varying degrees, including 10x Genomics, Vizgen, BioTechne, Bruker, Miltenyi Biotec, and Standard BioTools. Some competitors possess greater financial resources, larger research and development teams, or more established marketing and sales operations. Additionally, certain competitors are developing novel technologies that may rival or replace the company's offerings. The company attributes its market position to proprietary technologies, product development processes, scalable infrastructure, and customer experience. The spatial biology market is highly competitive, and unsuccessful competition could affect the company's revenue and profitability.
November 5, 2024
Transforming Immuno-Oncology: Akoya Biosciences Innovative Leap with the PhenoCode Discovery IO60 Amidst Market ChallengesIn the realm of immuno-oncology, few developments are as pivotal as the technologies that emerge to advance our understanding of tumor microenvironments and the immune responses they provoke. Akoya Biosciences Inc. a prominent entity in this field, has recently launched the PhenoCode Discovery IO60, a groundbreaking product designed to revolutionize spatial content innovation for researchers focused on immuno-oncology. Notably, this product release comes during a time of mixed financial performance for Akoya, with the company reporting a decline in revenue while many of its competitors ...
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Singular Genomics Systems Inc is a company that offers next-generation sequencing (NGS) solutions for genomics research. They provide an integrated platform that combines sample preparation, sequencing, and data analysis, enabling researchers to efficiently analyze complex genetic information.
Pacific Biosciences Of California Inc Share Performance
-27.45%
This Year
Pacific Biosciences Of California Inc
Profile
Pacific Biosciences of California Inc's business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.
Pressure Biosciences Inc's business model revolves around developing and commercializing advanced pressure-based technologies and products for various industries, including life sciences and biotechnology. Their innovative instruments and systems utilize pressure to effectively control and manipulate biological substances for various applications, such as cell disruption, sample preparation, protein extraction, and other related processes.
Rapid Micro Biosystems Inc has a business model centered around providing automated microbial detection and enumeration solutions for pharmaceutical companies, ensuring streamlined and efficient quality control processes. Their innovative technology enables rapid detection of microbial contamination in products, reducing the need for manual intervention and accelerating time-to-results for manufacturers.
Sources:
Akoya Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Akoya Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
